JY
VRPX

Jeff Yass’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Jeff Yass’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71
Closed -$5.59K – 13762
2023
Q4 		$5.59K Buy
+71
New +$10.6K ﹤0.01% 12122

Other funds holding VRPX

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Jeff Yass's VRPX Position: Q1 2024 in Review

Jeff Yass sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 71 shares — an estimated $5.59K sold.

Jeff Yass first reported a position in VRPX in Q4 2023 and held it in 1 quarter. The position peaked at $5.59K in Q4 2023. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

  • Jeff Yass reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Jeff Yass sold 71 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $5.59K.
  • Jeff Yass first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Jeff Yass's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $5.59K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.